Clinical Trial Update: A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study of Eplontersen in healthy Chinese volunteers completed to assess pharmacokinetics, pharmacodynamics, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: AstraZeneca | Conditions: Transthyretin-mediated Amyloidosis | Phase 1 | Status: COMPLETED